Preconditioning regimen consisting of anti-CD20 monoclonal antibody infusions, splenectomy and DFPP-enabled non-responders to undergo ABO-incompatible kidney transplantation-Reference-Cited by-同舟云学术

Preconditioning regimen consisting of anti-CD20 monoclonal antibody infusions, splenectomy and DFPP-enabled non-responders to undergo ABO-incompatible kidney transplantation

Published:2004-06 Issue:3 Volume:18 Page:254-260
ISSN:0902-0063
Container-title:Clinical Transplantation
language:en
Short-container-title:Clin Transplant

Author:

Sawada Tokihiko,Fuchinoue Shohei,Kawase Tomonori,Kubota Keiichi,Teraoka Satoshi

Publisher

Wiley

Subject

Transplantation

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1399-0012.2004.00151.x/fullpdf

Reference9 articles.

1. Successful A1-to-O ABO-incompatible kidney transplantation after a preconditioning regimen consisting of anti-CD20 monoclonal antibody infusions, splenectomy, and double-filtration plasmapheresis

2. Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma

3. Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis

Cited by 67 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Novel Flow Cytometry Method Detecting Complement C1q Bound to Blood Type A/B IgG Antibody for Preventing Severe Antibody-Mediated Rejection in ABO-Incompatible Kidney Transplantation;Antibodies;2024-08-01

2. Enhancing Success in the ABO-Incompatible Kidney Transplantation: A Case Report;Cureus;2024-06-14

3. FEASIBILITY OF THE AUTOMATED COLUMN AGGLUTINATION TECHNIQUE FOR TITRATION OF ANTI-A/B ANTIBODIES IN ABO-INCOMPATIBLE LIVING KIDNEY TRANSPLANTATION;Japanese Journal of Transfusion and Cell Therapy;2022-06-24

4. Feasibility of the automated column agglutination technique for titration of anti‐A /B antibodies in ABO ‐incompatible living kidney transplantation;Therapeutic Apheresis and Dialysis;2021-12

5. Desensitization Regimen Consisting of High-Dose Intravenous Immunoglobulin, Plasmapheresis, and Rituximab (an Anti-CD20 Antibody), Without Eculizumab and/or Bortezomib, in 41 Highly Sensitized Kidney Transplant Recipients;Experimental and Clinical Transplantation;2021-10